ReviewMolecular and cellular endocrinology2014
Genetics and epigenetics of sporadic thyroid cancer.
Review in Molecular and cellular endocrinology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- State of the Art on Thyroid Cancer Biology and Oncology.Biomedicines · 2026Review
- An Integrated Approach Combining Chemical Profiling, Network Pharmacology, and Experimental Validation Is Used to Clarify the Pharmacological Basis of the Yiqi-Tongluo-Huoxue-Mingmu Formula in Diabetic Retinopathy.Journal of diabetes research · 2026Article
- Article
- Article
- Liquid Biopsies in Follicular Thyroid Carcinomas-A Brief Report.Diagnostics (Basel, Switzerland) · 2024Article
- Association of Promoter Methylation Patterns with Expression of MAPK14 in Tissue of Papillary Thyroid Cancer Patients.Asian Pacific journal of cancer prevention : APJCP · 2023Article
- The Role of Exosomes in Epithelial-to-Mesenchymal Transition and Cell Functional Properties in Head and Neck Cancer.Cancers · 2023Review
- Targeting Autophagy in Thyroid Cancer: EMT, Apoptosis, and Cancer Stem Cells.Frontiers in cell and developmental biology · 2022Review
- Thyroid Cancer Stem-Like Cells: From Microenvironmental Niches to Therapeutic Strategies.Journal of clinical medicine · 2021Review
- Limited Clinical and Diagnostic Utility of Circulating Tumor DNA Detection in Patients with Early-Stage Well-Differentiated Thyroid Cancer: Comparison with Benign Thyroid Nodules and Healthy Individuals.Healthcare (Basel, Switzerland) · 2021Article
- Evaluation of the diagnostic performance of contrast-enhanced ultrasound combined withGland surgery · 2021Article
- Study on the Antitumor Effect and Glycolysis of Andrographolide in Anaplastic Thyroid Carcinoma.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- BRAFWorld journal of surgical oncology · 2020Article
- Investigation of promoter methylation of FSCN1 gene and FSCN1 protein expression in differentiated thyroid carcinomas.Molecular biology reports · 2020Article
- Cancer Stem Cells in Thyroid Tumors: From the Origin to Metastasis.Frontiers in endocrinology · 2020Review
- MOF Regulates TNK2 Transcription Expression to Promote Cell Proliferation in Thyroid Cancer.Frontiers in pharmacology · 2020Article
- Genome-wide association study of circulating folate one-carbon metabolites.Genetic epidemiology · 2019Article
- Review
- DNA methylation alterations as therapeutic prospects in thyroid cancer.Journal of endocrinological investigation · 2019Review
- Up-Regulated AKR1C2 is correlated with favorable prognosis in thyroid carcinoma.Journal of Cancer · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Thyroid carcinoma is the most common endocrine malignancy, and although the disease generally has an excellent prognosis, therapeutic options are limited for patients not cured by surgery and radioiodine. Thyroid carcinomas commonly contain one of a small number of recurrent genetic mutations. The identification and study of these mutations has led to a deeper understanding of the pathophysiology of this disease and is providing new approaches to diagnosis and therapy. Papillary thyroid carcinomas usually contain an activating mutation in the RAS cascade, most commonly in BRAF and less commonly in RAS itself or through gene fusions that activate RET. A chromosomal translocation that results in production of a PAX8-PPARG fusion protein is found in follicular carcinomas. Anaplastic carcinomas may contain some of the above changes as well as additional mutations. Therapies that are targeted to these mutations are being used in patient care and clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.